Clinical trial

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of…

NCT00192322 · MedImmune LLC, Industry · Completed

Key facts

NCT number NCT00192322
Title Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
Official title A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live Cold Adapted (CAIV-T) in Healthy Children Aged 6 to Less Than 36 Months
Acronym CAIVT
Lead sponsor MedImmune LLC, Industry
Collaborators Wyeth is now a wholly owned subsidiary of Pfizer Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Influenza
Intervention type Biological
Interventions CAIV-T 10^7, CAIVT 10^5, Placebo, TIV
Enrollment 173
Start date Sep 1, 2001
Primary completion Dec 1, 2001
Completion Dec 1, 2001
First posted Sep 19, 2005
Last update posted Feb 17, 2012
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies